2025
Combined atherectomy and intravascular lithotripsy in calcified coronary lesions: a meta-analysis.
Singh S, Garg A, Tantry U, Bliden K, Gurbel P, Kochar A, Nanna M, Damluji A. Combined atherectomy and intravascular lithotripsy in calcified coronary lesions: a meta-analysis. Journal Of Invasive Cardiology 2025 PMID: 39993271, DOI: 10.25270/jic/24.00312.Peer-Reviewed Original ResearchCalcified coronary lesionsProcedural success rateCoronary lesionsIntravascular lithotripsyCoronary perforationRisk of procedural complicationsRisk of adverse CV eventsAcute procedural successSuccess rateAcute coronary syndromeAdverse CV eventsTarget vessel revascularizationSeverely calcified coronary lesionsRandom-effects modelTreatment of severely calcified coronary lesionsPeriprocedural complicationsPooled proportionProcedural complicationsProcedural successCV deathCoronary syndromeCV eventsFollow-upProcedural outcomesCV outcomes
2022
Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS
Anam A, Inzucchi S. Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS. 2022, 527-553. DOI: 10.1007/978-3-030-92589-5_26.ChaptersPolycystic ovary syndromeType 2 diabetes mellitusDiabetes mellitusSodium-glucose cotransporter 2 inhibitorsGLP-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsWeight lossGLP-1 RAsCV risk factorsGlucose-lowering medicationsCotransporter 2 inhibitorsGlucose lowering medicationsPeptidase-4 inhibitorsHigh-risk populationCategories of medicationsAbnormal carbohydrate metabolismPart of standardCV outcomesLifestyle interventionOvary syndromeMetabolic sequelaeMetabolic abnormalitiesMetabolic managementSGLT2 inhibitorsPatient population
2021
ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL
Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2021, 37: s62-s63. DOI: 10.1016/j.cjca.2021.07.130.Peer-Reviewed Original ResearchEMPA-REG OUTCOME trialKidney eventsOutcome trialsPlacebo armMyocardial infarctionType 2 diabetes mellitusLower baseline eGFRMI/strokeSubsequent CV eventsRisk of hospitalizationCoronary artery diseaseType 2 diabetesHigh uric acidUse of therapiesAssociation of kidneyBaseline eGFRCV eventsCV outcomesSubsequent HHFCardiovascular outcomesHF outcomesArtery diseaseBaseline factorsDiabetes mellitusHeart failure
2020
Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial
Yaggi H, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi S, Wanner C, Zwiener I, Wojeck B, Neeland I, Johansen O. Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial. European Heart Journal 2020, 41: ehaa946.2883. DOI: 10.1093/ehjci/ehaa946.2883.Peer-Reviewed Original ResearchEMPA-REG OUTCOMECardiovascular diseaseIncidence rateMajor adverse CV eventsPlacebo-controlled outcome trialsAdverse CV eventsGlomerular filtration rateSystolic blood pressureCox regression modelStandard of careType 2 diabetesCV deathCV eventsCV outcomesMultivariable adjustmentInhibitor empagliflozinOutcome trialsBlood pressureHeart failureWaist circumferenceMortality outcomesSodium glucoseFiltration rateMetabolic disturbancesPatientsThe Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial
Neeland IJ, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi SE, Wanner C, Zwiener I, Wojeck BS, Yaggi HK, Johansen OE. The Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020, 43: 3007-3015. PMID: 33004464, PMCID: PMC7770278, DOI: 10.2337/dc20-1096.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaRenal outcomesOSA statusSleep apneaNew-onset obstructive sleep apneaMultivariable-adjusted Cox regression modelsBaseline obstructive sleep apneaMajor adverse CV eventsEMPA-REG OUTCOME trialEMPA-REG OUTCOMEImpact of empagliflozinPlacebo-adjusted reductionsAdverse CV eventsEffect of empagliflozinHeart failure hospitalizationSystolic blood pressureCox regression modelStandard of careCV deathCV eventsCV outcomesEMPA-REGEmpagliflozin treatmentRenal eventsCV disease
2019
159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME
ZINMAN B, FITCHETT D, MATTHEUS M, WANNER C, GEORGE J, VEDIN O, INZUCCHI S, JOHANSEN O. 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME. Diabetes 2019, 68 DOI: 10.2337/db19-159-lb.Peer-Reviewed Original ResearchEMPA-REG OUTCOMEAdverse eventsBoehringer Ingelheim PharmaceuticalsPlasma glucoseMyocardial infarctionCause deathCV outcomesJanssen PharmaceuticalsType 2 diabetes mellitusEli LillyRisk of MIHeart failure hospitalizationRisk of HHFCardio-protective effectsCox regression modelAdvisory PanelCV deathCV diseaseFailure hospitalizationPlacebo groupDiabetes mellitusDohme Corp.Novo Nordisk A/STime-varying covariatesMerck Sharp
2017
Pioglitazone and cardiovascular risk reduction
Perdigoto AL, Young LH, Inzucchi SE. Pioglitazone and cardiovascular risk reduction. Cardiovascular Endocrinology & Metabolism 2017, 6: 55-61. PMID: 31646121, PMCID: PMC6768516, DOI: 10.1097/xce.0000000000000110.Peer-Reviewed Original ResearchInsulin Resistance InterventionCV outcomesInsulin resistanceResistance InterventionImpact of thiazolidinedionesCardiovascular risk reductionGlucose-lowering drugsCardiovascular disease riskInsulin-resistant patientsType 2 diabetesCV complicationsMacrovascular eventsCV riskSecondary preventionResistant patientsStroke patientsStroke trialsPathophysiological abnormalitiesAntihyperglycemic agentsInsulin sensitivityDiabetes managementClinical practiceStroke resultsPatientsDisease risk
2015
Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure
Motiwala SR, Gaggin HK, Gandhi PU, Belcher A, Weiner RB, Baggish AL, Szymonifka J, Januzzi JL. Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure. Journal Of Cardiovascular Translational Research 2015, 8: 164-172. PMID: 25777344, DOI: 10.1007/s12265-015-9618-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersChi-Square DistributionChronic DiseaseDisease ProgressionFemaleHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardiumNatriuretic Peptide, BrainNecrosisOdds RatioPeptide FragmentsPhenotypePredictive Value of TestsPrognosisProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective StudiesRisk FactorsSystoleTime FactorsTroponin IVentricular Dysfunction, LeftVentricular Function, LeftVentricular RemodelingConceptsLV systolic dysfunctionChronic heart failureHeart failureLV remodelingSerial measurementsHigh-risk clinical featuresLower CV event ratesCV event ratesDeleterious LV remodelingIndependent risk informationPoor cardiovascular outcomesPoor CV outcomesProgressive LV remodelingSensitive cardiac troponinMajority of patientsSignificant myocardial necrosisSensitive troponin assaysPg/mLCV outcomesHsTnI concentrationsCardiovascular eventsCardiovascular outcomesSystolic dysfunctionAdverse remodelingClinical features
2012
Risk of cardiovascular events in patients with polycystic ovary syndrome.
Iftikhar S, Collazo-Clavell M, Roger V, St Sauver J, Brown R, Cha S, Rhodes D. Risk of cardiovascular events in patients with polycystic ovary syndrome. The Netherlands Journal Of Medicine 2012, 70: 74-80. PMID: 22418753, PMCID: PMC3582228.Peer-Reviewed Original ResearchConceptsPolycystic ovary syndromeCV eventsLipoprotein cholesterolOvary syndromeRisk factorsCoronary artery bypass graft surgeryRochester Epidemiology Project resourcesArtery bypass graft surgeryHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolType 2 diabetes mellitusHigher Body Mass IndexBypass graft surgeryCardiovascular risk factorsCV risk factorsRetrospective cohort studyAdverse CV outcomesBody mass indexCV outcomesCardiovascular eventsCV diseaseGraft surgeryOlmsted CountyCohort studyPCOS diagnosis
2011
Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs.
Ruff CT, Morrow DA, Jarolim P, Ren F, Contant CF, Kaur A, Curtis SP, Laine L, Cannon CP, Brune K. Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. The Journal Of Rheumatology 2011, 38: 1071-8. PMID: 21459935, DOI: 10.3899/jrheum.100880.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Inflammatory Agents, Non-SteroidalArthritis, RheumatoidBiomarkersC-Reactive ProteinCardiovascular DiseasesDiclofenacEtoricoxibFemaleHeart FailureHumansLongitudinal StudiesMaleMiddle AgedMyocardial InfarctionNatriuretic Peptide, BrainOsteoarthritisPeptide FragmentsProspective StudiesPyridinesRetrospective StudiesRisk FactorsSulfonesThrombosisTreatment OutcomeConceptsHigh-sensitivity C-reactive proteinNonsteroidal antiinflammatory drugsSensitivity C-reactive proteinNT-proBNPC-reactive proteinHeart failureCV eventsCV outcomesCV riskThrombotic eventsMyocardial infarctionAntiinflammatory drugsBiomarkers N-terminal pro-B-type natriuretic peptideCardiac biomarkers N-terminal pro-B-type natriuretic peptideN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideChronic nonsteroidal antiinflammatory drugsBaseline NT-proBNPChronic NSAID treatmentLow CV riskNT-proBNP levelsFuture cardiovascular eventsBody mass indexIdentification of patientsTypes of arthritis
2010
Evidence for the efficacy of ARBs across the cardiovascular continuum
Gupta M, Honos GN, Velazquez EJ, Chung N, Oigman W, Maggioni AP. Evidence for the efficacy of ARBs across the cardiovascular continuum. Current Medical Research And Opinion 2010, 26: 1203-1218. PMID: 20302552, DOI: 10.1185/03007991003712159.Peer-Reviewed Original ResearchConceptsAngiotensin II receptor blockersPatient populationARB classCV continuumPre-specified risk factorsMajor CV outcomesII receptor blockersPrimary prevention studiesCardiovascular disease riskAdditional patient populationsDifferent patient populationsNumerous patient populationsMajor literature databasesCardiovascular continuumCV eventsCV morbidityCV outcomesReceptor blockersSecondary preventionACE inhibitorsAntihypertensive agentsOngoing trialsPrevention StudyRisk factorsDisease risk
2009
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP, Investigators F. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal Of Heart Failure 2009, 11: 292-298. PMID: 19176539, PMCID: PMC2645058, DOI: 10.1093/eurjhf/hfp001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAtherosclerosisCause of DeathConfidence IntervalsDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionOdds RatioPrognosisProportional Hazards ModelsProspective StudiesPulmonary Disease, Chronic ObstructiveSurvival RateTetrazolesTime FactorsValineValsartanConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAcute Myocardial Infarction trialMyocardial Infarction trialPulmonary diseaseAcute myocardial infarctionAtherosclerotic eventsMyocardial infarctionIndependent predictorsCV outcomesHazard ratioNon-fatal clinical eventsNon-CV deathAdjusted hazard ratioMajor cardiovascular eventsHigh-risk patientsRisk of deathProportional hazards modelMode of deathMedian followCardiovascular eventsCause mortalityAirway diseaseMultivariate adjustmentUnadjusted risk
2008
Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus
Anavekar NS, Solomon SD, McMurray JJ, Maggioni A, Rouleau JL, Califf R, White H, Kober L, Velazquez E, Pfeffer MA. Comparison of Renal Function and Cardiovascular Risk Following Acute Myocardial Infarction in Patients With and Without Diabetes Mellitus. The American Journal Of Cardiology 2008, 101: 925-929. PMID: 18359309, DOI: 10.1016/j.amjcard.2007.11.037.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionRenal dysfunctionRenal functionMyocardial infarctionCV outcomesDiabetes mellitusHigh-risk acute myocardial infarctionCox proportional modelingAdverse CV outcomesComposite cardiovascular eventsComposite end pointIndependent risk factorRenal Disease equationGlomerular filtration rateReduced renal functionBaseline creatinineCV eventsMean eGFRCardiovascular eventsCV diseaseCV riskVentricular dysfunctionCardiovascular riskHeart failureOverall mortalityUsefulness of Right Ventricular Fractional Area Change to Predict Death, Heart Failure, and Stroke Following Myocardial Infarction (from the VALIANT ECHO Study)
Anavekar NS, Skali H, Bourgoun M, Ghali JK, Kober L, Maggioni AP, McMurray JJ, Velazquez E, Califf R, Pfeffer MA, Solomon SD. Usefulness of Right Ventricular Fractional Area Change to Predict Death, Heart Failure, and Stroke Following Myocardial Infarction (from the VALIANT ECHO Study). The American Journal Of Cardiology 2008, 101: 607-612. PMID: 18308007, DOI: 10.1016/j.amjcard.2007.09.115.Peer-Reviewed Original ResearchConceptsRight ventricular fractional area changeVentricular fractional area changeRight ventricular functionHeart failureFractional area changeMyocardial infarctionClinical outcomesSudden deathCause mortalityVentricular dysfunctionEjection fractionVentricular functionBaseline right ventricular functionRight ventricular systolic functionSevere right ventricular dysfunctionLeft ventricular ejection fractionRecurrent myocardial infarctionRight ventricular dysfunctionLeft ventricular dysfunctionVentricular systolic functionVentricular ejection fractionMajor risk factorTwo-dimensional echocardiogramsCV deathCV outcomes
2006
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
Janardhanan R, Kenchaiah S, Velazquez EJ, Park Y, McMurray JJ, Weaver WD, Finn PV, White HD, Marin-Neto JA, O'Connor C, Pfeffer MA, Califf RM, Solomon SD, Investigators F. Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. American Heart Journal 2006, 152: 183-189. PMID: 16824854, DOI: 10.1016/j.ahj.2005.11.013.Peer-Reviewed Original ResearchConceptsExtent of CADCoronary artery diseaseAcute myocardial infarctionHeart failureCV outcomesMyocardial infarctionCause mortalityArtery diseaseSeverity of CADVentricular systolic dysfunctionAdverse CV outcomesHigh-risk patientsIndependent risk factorSingle-vessel diseasePredictors of outcomeProportional hazards modelCoronary angiography dataCaptopril monotherapyValsartan monotherapyCardiovascular outcomesSystolic dysfunctionVentricular dysfunctionHazard ratioEjection fractionPoor outcome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply